The central immunological disturbance in patients with SLE is autoantibody production 13 . These antibodies are directed at several self molecules found in the nucleus, cytoplasm, and cell surface, in addition to soluble molecules such as IgG and coagulation factors. The production of antibodies result from complex mechanisms involving every key facet of the immune system. It appears that excessive and uncontrolled T cell help in the differentiation and activation of auto antibody forming B cells is probably a final common pathway. The abnormal cellular and humoral response to the formation of auto antibodies is modulated by genetic, environmental, and hormonal factors 12 .
Genetic factors
• Genes of the MHC HLA-Al, B8 and DR3 have been linked to lupus.
• Genetic deficiency of complement factors C 1 q, C 2 , C 4 have also been linked to lupus.
Environmental factors
• Occupational exposure -Silica, pesticides, mercury etc.
• Drugs
• Sunlight
• Epstein -Bar Virus (EBV) has also been identified as a possible factor in the development of lupus.
Hormones
Steroids have many effects on both the innate and adaptive immune systems and are therefore of importance in disease pathogenesis. Although sex hormones do not cause SLE, they probably play a role in disease predisposition, severity and activity 6 .
The basic pathological features of SLE are that of inflammation and blood vessel abnormalities, which include band or occlusive vasculopathy, vasculities, and immune complex deposition 13 . The best characterised organ pathology is in the kidney. By light and immuno-fluorescence microscopy, renal biopsies in SLE patients display mesangial cell proliferation, inflammation, basement membrane abnormalities, and immune complex deposition.
Other organ systems affected by SLE usually display non-specific inflammation or vascular abnormalities, although pathological findings are sometimes minimal. Occlusive vasculopathy is a common histological feature associated with presence of antiphospholipid antibodies. Atherosclerosis and tissue damage caused by hypertension, corticostetesoids, and other drugs can be found in patients with long standing SLE.
Clinical Presentation:
Children with lupus present with diverse and often severe manifestations (Table-I ). Most frequently they present with systemic, constitutional symptoms such as fever, diffuse hair loss, fatigue, weight loss, and evidence of diffuse inflammation as demonstrated by lymphadenopathy and hepotosplenomegaly 2 . These manifestations may be seen throughout the course of the disease or intermittently. Skin, musculoskeletal, and renal systems are the most common organ involved in childhood SLE. Carreno et al in their study found a higher frequency of cutaneous vasculitis, seizures, nephropathy and discoid lupus erythematous in childhood SLE 14 . On the other hand adults had more incidence of articular manifestations. Some other studies also observed a higher frequency of renal disease, chorea, central nervous system involvement or hematological findings among childhood SLE 15, 16 .
In a recent meta analysis significant differences were found in clinical manifestations between childhoodonset lupus and adult-onset lupus 17 . Malar rash, ulcers/mucocutoneous involvement, renal involvement, seizures, thrombocytopenia, hemolytic anemia, fever and lymphadenopathy were common in childhood-onset SLE with ORs ranging from 1.3 to 3.7. However, Raynauds, pleuritis, and sicca were more common in adult-onset SLE.
Overall 60-80% of children with SLE have abnormalities of the urinary tests or of renal function early in the course of the disease. In 90% of patients, renal disease occurs within two years from disease onset 18 . Some children may present solely with renal disease, with a picture of nephrotic syndrome; rarely a child or teen may present with renal failure at the onset 19 .
Another study comparing childhood SLE with adult onset SLE done in a multicenter, multiethnic disease cohort showed that juvenile onset patients had significantly more renal and neurologic involvement at the time of entry into the study 20 . These patients also had more active disease at diagnosis, as measured by valid disease activity measure.
Neurologic manifestations of SLE are difficult to diagnose because they may be vague and varied 10 . After renal disease, neurologic problem is the second leading cause of serious morbidity and mortality. Psychiatric manifestations including psychosis, seizures and headaches are the most commons CNS symptoms. Headaches, difficulty with concentration or memory, depression or a decline in school performance, all may be due to lupus cerebritis but also may result from coping difficulties with a chronic illness or an effect of steroid treatment 10 .
The World Health Organization (WHO) has defined a morphologic classification of kidney biopsies in SLE, and this classification was revised in 2003 by the International Society of Nephrology and the Renal Pathology Society 2 . The histologic classes range from normal by light microscopy (class1) to advanced sclerotic nephritis (class VI). It is well recognised that patients with class IV nephritis can present with a normal serum creatinine level, blood pressure and with minimally active urine sediment. Because treatment differs, a renal biopsy is warranted at the time of initial presentation in patients with an active urine sediment or abnormal renal function 2 . At disease onset, more severe proteinuria, more haematuria, a lower serum albumin and the need for antihypertensive drugs are all associated with a higher class of lupus nephritis 18 .
Hematologic Involvement
Anemia, thrombocytopenia, and leukopenia are seen in 50% to 75% of patients. The coombs' test is positive in approximately 30% to 40% of patients, but less than 10% of patients have overt hemolysis 2, 21 . Thrombocytopenia may be the initial presentation in up to 15% of pediatric cases. Patients with chronic autoimmune idiopathic thrombocytopenic purpura should be assessed for the presence of antinuclear antibodies, as they are at high risk of developing SLE.
Cardiovascular involvement
Any layer of the heart may be involved in SLE, although the pericardium in affected most commonlty 10 . Less commonly, endo-or myocarditis or vulvular disease is found, and rarely, ishchaemic heart disease may result secondary to coronary artery vasculitis 22 . Vulvular abnormalities are frequent in patients with SLE among which mitral valve lesions being most common 23 .
Other cardiovascular abnormalities include raised pulmonary artery pressure, pericardiul effusion, hypokinesis and aortic insufficiency.
The major cardiovascular morbidity associated with SLE is premature atherosclerosis. A number of atherosclerotic risk factors, including lipid abnormalities, altered endothelial function, nephritis, and protienurea have been implicated in the development of premature atherosclerosis in patients with childhood SLE.
Pulmonary involvement
Pulmonary involvement is common in childhood SLE and occurs in 25% to 75% of cases 2 . The clinical spectrum includes pleuritis, pneumonitis, pulmonary haemorrhage, pulmonary hypertension, and pneumothorax. Patients with SLE receiving immunosuppressive therapy are at high risk for infection with opportunistic organisms including Herpes viruses, Pneumo-cystis carini and fungal infections. These infections must be ruled out before the indroduction of significant immunosuppressive therapy.
Gastrointestinal involvement
Gastrointestinal involvement occurs in 20% to 40% of patients 2 . Abdominal pain can result from peritoneal inflammation (serositis), vasculitis, pancreatits, malabsoption, pseudo-obstruction, paralytic ilcus, or direct bowel wall involvement (enteritis).
Diagnosis of childhood SLE:
Early diagnosis is the key to getting the best possible outcome for children with SLE. With early diagnosis and treatment, much of the long-term organ damage can be prevented and the prognosis is greatly improved 24 . The most important cause for delay in the diagnosis is the failure of the initial physician/ paediatrician to consider the possibility of a lupus diagnosis.
The diagnosis of lupus is confirmed by the combination of clinical and laboratory manifestations revealing a multisystem disease 1 . The revised ACR classification criteria are commonly used by the rheumatologistis to diagnose SLE, although these criteria were not specifically developed as diagnostic creiteria 24 . The criteria were created to allow physicians to exclude patients who most definitely did not have SLE.
The presence of 4 of 11 criteria (Table- 2) serially or simultaneously strongly suggests the diagnosis 25 . Unfortunately, they don't include the most common initial symptoms of SLE, which are fever, malaise (not feeling well), and aches and pains. Children with SLE Some SLE children have a long history of being evaluated always "without explanation" -for aneamia, easy bruising, or fatigue, fever and weight loss. There is a wide variety of other "unexplained" findings. At the same time, all of these findings may be caused by many different diseases. So, how to proceed? If physicians remember that lupus is one of the possibilities in children who becomes ill, they should include Anti-nuclear antibodies (ANA) in the laboratory test 24 . But ANA should be done by Immunofluorescence Assay method using Hep2 cell line 26 . It has been shown that sensitivity of this method is much higher than that of ELISA method [26] [27] [28] .
A positive ANA test should prompt further consideration of SLE, and more complete testing is needed to seek evidences of SLE ( Figure 1 ). This is where it becomes important to consider the presence or abscence of ACR critaeria for a "definite diagnosis of SLE" 24 .
Auto antibodies are typically present years before the diagnosis of SLE [29] [30] . Furthermore, the appearance of autoantibodies in patients with SLE tends to follow a predictable course, with a progressive accumulation of specific antibodies before the onset of SLE, while patients are still asymptomatic 29 .
Investigations in a suspected case of SLE Any antibody to nuclear components is an ANA 27 . Most patients with positive ANAs do not have SLE, but most people with SLE have positive ANAs. Today's ANA test is very sensitive (it detects almost every case of SLE), but it is not very specific 24 . According to a guideline from College of American Pathologists (CAP), no further laboratory tests are necessary for diagnosing SLE in patients who meet ACR diagnostic criteria and also have positive ANA 31 .
Testing for antibody to double-stranded DNA antigen (anti-ds DNA) and antibody to sm nuclear antigen (antism) may be helpful in patients who have a positive ANA test but do not meet full criteria for the diagnosis of SLE 32 . Anti-ds DNA antibodies are associated with systemic lupus and nephritis, but not subacute cutaneous lupus or discoid lupus. Antibodies to ENAs (Anti-RO/La antibodies) are very useful when anti-ds DNA or anti-sm are absent 27 .
Indicators of Inflammation
Most acute phase indices of inflammation are increased in children in proportion to the activity of the systemic disease 6 . These include an increased erythrocyte sedimentation rate (ESR), polyclonal hyper gammaglobulinaemia and increased level of µ 2 -globulins 27 . C-reactive protein (CRP), an important acute phase protein that is elevated in most inflammatory conditions, is often normal. However, it is increased in patients with SLE and systemic infection and in those with serositis or arthritis 33, 34 .
Haematologic abnormalities Aneamia
Mild or moderate anaemia occurs in approximately one half of children with SLE and is usually typical of chronic disease. In other patients, it reflects autoimmune haemolysis caused by IgG complement fixing antibodies to erythrocytes that are detected by an antiglobulin test (coomb's test) 6 .
Leukocytes and platelets
Although leukocytosis may occur, lymphocytopenia is common in patients with active disease and neutropenia often along with thrombocytopenia is found in upto 50% of these patients 35, 36 . Patients with immune thrombocytopenic purpura and haemolytic aneamia may progress to SLE. 
Urine analysis
Most childhood lupus nephritis have abnormalities of the urinary sediment. Proteinuria is probably the most common abnormality, but haematuria and red blood cell casts are more important hall marks of active glomerulonephritis 18 .
Antiphospholipid antibodies
Anticardiolipin antibodies (ACAs) of all iso-types are found in 16-60% patients with SLE 27 . IgG ACAs are a risk factor for thrombosis and the antiphospholipid syndrome.
Management of SLE
SLE is a chronic disease, characterized by remissions and relapses and associated with considerable morbidity and mortality. Treatment of SLE itself is associated with morbidity, the effects of which may be short term or permanent. So, counseling the child and the family is the first and foremost important aspect of management. In order to obtain optimal outcome from drug therapy, patient/family education plays a vital role and must be paid due attention.
General measures
Incorporation of the child and parents into the planning of the overall treatment program is best accomplished by informing them about the character, treatment and outcome of the disease 6 . As with other illness in childhood, rigorous restrictions on general activity are usually unnecessary and undesirable. Except during periods of severe active disease, school attendance should be encouraged.
Although no foods are directly helpful or detrimental to the patient with SLE, a well-balanced diet with appropriate calorie intake is important. Avoidance of "junc food" and food high in sodium helps to minimize excessive weight gain.
Sunlight is frequently responsible for exacerbations of lupus activity. Photosensitive patients must be advised to wear protective clothings with long sleeves. Use of suncreams with sun protection factor (spf) of more than 15 is necessary 37 . Umbrella should be used for protection from sunlight if going outside during daytime is essential.
Infections are common in SLE and they are very important cause of hospitalization and death 38 . All types of infections have been reported : bacterial, viral and opportunistics. Therefore patients must get any unexplained fever evaluated promptly. This is particularly important when lupus child is on long-term steroid/cytotoxic therapy. In order to prevent infections, it is important to optimize treatment by using the minimal effective dose of the drug to control the disease 39 .
Specific Drug therapy
Specific treatment should be individualized and based on the extent and severity of the disease.
Non-steroidal Anti-inflammatory Drugs (NSAIDS)
Myalgia, arthralgia or arthritis response well to antiinflammatory doses of NSAIDS. Low dose aspirin in indicated if the child has high titers of antiphospholipid antibodies.
Hydroxychloriquine
The role of hydroxychloroquine in the treatment of SLE is given much more importance than it was used to give in the past since the publication of the studies by the Canadian Hydroxychloroquine study group 40 . These studies reported that hydroxychloroquine reduces the frequency and severity of flares in SLE patients. It also may have a role in reversing glucocorticoid-induced changes in plasma lipids.
Corticosteroid therapy
Corticosteroids remain the back bone of treatment for SLE and are generally the first agent used 41 . Almost all children with SLE need oral prednisolone or intravenous methyl prednisolone at somestage of the disease. Prednisolone should be given in a dose sufficient to achieve disease control, often 1 to 2 mg/ kg/day. At the initiation of therapy, oral steroid should be prescribed in a divided doses to maximize the antiinflammatory and immuno-suppressive effects 6 . Lowdose prednisolone (<0.5mg/kg/day) is usually sufficient to control fever, dermatitis, arthritis and serositis. High dose prednisolone (1 to 2 mg/kg/day) is needed for treatment of severe type of lupus nephritis, CNS disease, acute haemolytic anaemia and parenchymal pulmonary disese. In addition I/V methyprednisolone (upto 30 mg/kg/day) in consecutive days may also be needed to manage the problems, particularly if a rapid response is needed.
Immunosuppressive Drugs
Immunosuppressive drugs like azothiarpine, cyclophosphamide (CYC), cyclosporine and mycophenolate mofetils are often required to control SLE and to improve the quality of life. A meta analysis done in adults with SLE cases found the superiority of immuno-suppressive drugs and prednisolone over prednisolone alone in lupus nephritis 42 . The choice immunosuppressive agents should be made depending to a large extent on the severity of the disease and specific organ involvement. Figure 2 shows current and future treatments of SLE 41 .
Rituximab
The role of B-cells in the pathogenesis of auto-immune disease is becoming increasingly clear. Rituximab (RTX) is a chimeric mouse/human monoclonal antibody. Treatment with RTX eliminates CD 20 positive B-cells both directly and by inducing apoptosis without inciting on inflammatory response in neighbouring cells 43 .
It is demonstrated that children with SLE respond well to the combination of RTX and CYC. Twelve patients aged 11-28 years (median 14 years) with active childhood onset SLE was treated with combination of RTX and CYC. SLEDAI scores improved significantly. Therapy was well tolerated and there was no serous adverse events 43 .
Belimumab
Recently FDA approved Belimumab (Benlysta), a new lupus drug which is designed to interfere with a protein critical to B cell activity, thus suppressing its autoimmunity 44 . In approving the drug, the FDA analyzed two trials involving 1,684 patients with lupus, some of whom were given the medication along with their current therapy, and others were given a placebo infusion. The treated patients recorded fewer episodes of disease activity than those on placebo, and some were able to lower the dose of steroids they needed to control their disease. These patients however, showed slightly higher rates of infections and mortality than the group that didn't receive Benlysta.
Autologous stem cell transplantation
In case of severe SLE, autologous stem cell transplantation after myeloablation with high dose cyclophosphamide had been performed with good short term effect. But it was associated with significant morbidity and mortality. Significant relapse rate was also reported in paediatric SLE 41 .
Prognosis
Survival of patients with systemic lupus erythematosus has increased remarkably in the last few decades, from 50% at 2 years in 1950 to more than 90% at 10 years in the 1990 and onwards 45 . While lupus can be a severe and life threatening disease, many children with lupus will do very well. The prognosis of lupus in childhood depends n the severity of the internal organ involvement. However, lupus is unpredictable and no one will be able to predict with certainty the long-term outcome for a specific child. The long term prognosis of these patients remains poor mainly due to complications of the disease and / or of its treatment.
Recurrent infections contribute significantly to the morbidity and mortality of children with SLE. Infections are important cause of hospitalization and death in SLE. All types of infections are reported : bacterial, viral and opportunistic 38 . Osteonecrosis occurs in 10% to 12% of patients and probably reflects the effects of disease and prolonged use of corticosteroids 46 . Although it is not associated with mortality, avascular necrosis contributes to significant morbidity and quality of life.
It has been clearly demonstrated that atherosclerosis is accelerated in patients with SLE 47 . Atherosclerosis usually become clinically apparent only after a decade or more of active disease. It is true that medical science has not yet developed a method for curing lupus. And some patients do die from the disease. However children with non-organ threatening aspects of lupus can look forward to a normal live-span if they :
• follow the instructions of their physician
• take their medications as prescribed, and
• know when to seek help for unexpected side effects of a medication or a new manifestations of their lupus.
So, every effort must be made to assure compliance with medications and follow up, since compliance is the single best predictor of disease outcome in children with SLE.
